<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211013052757N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-02-11</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of four flower herbal vaginal gel and auricular therapy on atrophic vaginitis</public_title>
      <acronym></acronym>
      <scientific_title>The effect of four flowers herbal vaginal gel and auriculotherapy in comparison with placebo on atrophic vaginitis in women referred to selected medical centers affiliated to Isfahan University of Medical Sciences in 2021</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60596</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: 90 patients were eligible to enter the study randomly, using the random number table available at the site, in two age groups under 60 years and over 60 years, in three groups of uriculotherapy, herbal gel and placebo (A, B, C) Will be divided. Because there is no possibility of blinding the participant and the researcher in the oriculotherapy group, group C will be known as the oriculotherapy group from the very beginning, Blinding description: Interventions in patients consuming vaginal gel and placebo are in the form of three blinds, so that the patient and the researcher are not aware that the patient is taking the drug or placebo.However, in the uriculotherapy group, due to the impossibility, blindness was not performed.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Volvovaginal atrophy.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: In the herbal vaginal gel group, in the first session after completing the forms, 4 tubes of vaginal gel  in 30 gram tubes  are delivered to the patient for consumption for four weeks. How to take the drug in the first 4 weeks: Every night before going to bed, use a 5-gram applicator inside the vagina and do not get up for a few hours to absorb the drug. And Women's Sexual Performance Index Questionnaire and Quality of Life Assessment Questionnaire will be completed for each.Then another 2 tubes are delivered to patients for consumption in the next 4 weeks. How to take the medicine in the second 4 weeks: One night before going to bed, use a 5 g applicator inside the vagina and do not get up for a few hours to absorb the medicine. At the end of 8 weeks of intervention, the forms will be completed again. Intervention 2: Second intervention group: In the case of the uriculotherapy group, the patient visits for uricotherapy once a week from the beginning of the study.At each visit, the points related to vaginal atrophy in the ear were identified first and then placed on the points related to Seyed Vakaria. The patient is instructed to press each side for 1 minute every hour (except when the patient is asleep). There is no problem in taking a shower while the patient is sick.Forms and questionnaires in the uriculotherapy group will be completed at the beginning of the intervention, the end of the fourth week and the end of the eighth week. Intervention 3: Control group: In the control group, in the first session after completing the forms, 4 tubes of  placebo in 30 gram tubes in a completely uniform shape are delivered to the patient for consumption for four weeks. How to take the drug in the first 4 weeks: Every night before going to bed, use a 5-gram applicator inside the vagina and do not get up for a few hours to absorb the drug. And Women's Sexual Performance Index Questionnaire and Quality of Life Assessment Questionnaire will be completed for each.Then another 2 tubes are delivered to patients for consumption in the next 4 weeks. How to take the medicine in the second 4 weeks: One night before going to bed, use a 5 g applicator inside the vagina and do not get up for a few hours to absorb the medicine. At the end of 8 weeks of intervention, the forms will be completed again.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Elahe Naderiafshar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Iranian Medicine, School of Medicine, Isfahan University of Medical Sciences, Hezar Jarib St.</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3792 8155</telephone>
        <email>e.naderiafshar@resident.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Elahe Naderiafshar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Iranian Medicine, School of Medicine, Isfahan University of Medical Sciences, Hezar Jarib St.</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3792 8155</telephone>
        <email>e.naderiafshar@resident.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age: 45 to 65 years old
12 months have passed since menopause
Symptoms of vaginal atrophy
Patient consent to participate in the project
Being married
Natural Pap smear in the past year</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Breast or uterine cancer
Abnormal vaginal bleeding
Vaginal device abnormalities
Taking oral hormonal medication 8 weeks before treatment
Use of topical hormonal creams or topical lubricants in the last month</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N95.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Postmenopausal atrophic vaginitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>Behavior</i_code>
      <i_code>Behavior</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: In the herbal vaginal gel group, in the first session after completing the forms, 4 tubes of vaginal gel  in 30 gram tubes  are delivered to the patient for consumption for four weeks. How to take the drug in the first 4 weeks: Every night before going to bed, use a 5-gram applicator inside the vagina and do not get up for a few hours to absorb the drug. And Women's Sexual Performance Index Questionnaire and Quality of Life Assessment Questionnaire will be completed for each.Then another 2 tubes are delivered to patients for consumption in the next 4 weeks. How to take the medicine in the second 4 weeks: One night before going to bed, use a 5 g applicator inside the vagina and do not get up for a few hours to absorb the medicine. At the end of 8 weeks of intervention, the forms will be completed again.</i_keyword>
      <i_keyword>Second intervention group: In the case of the uriculotherapy group, the patient visits for uricotherapy once a week from the beginning of the study.At each visit, the points related to vaginal atrophy in the ear were identified first and then placed on the points related to Seyed Vakaria. The patient is instructed to press each side for 1 minute every hour (except when the patient is asleep). There is no problem in taking a shower while the patient is sick.Forms and questionnaires in the uriculotherapy group will be completed at the beginning of the intervention, the end of the fourth week and the end of the eighth week.</i_keyword>
      <i_keyword>Control group: In the control group, in the first session after completing the forms, 4 tubes of  placebo in 30 gram tubes in a completely uniform shape are delivered to the patient for consumption for four weeks. How to take the drug in the first 4 weeks: Every night before going to bed, use a 5-gram applicator inside the vagina and do not get up for a few hours to absorb the drug. And Women's Sexual Performance Index Questionnaire and Quality of Life Assessment Questionnaire will be completed for each.Then another 2 tubes are delivered to patients for consumption in the next 4 weeks. How to take the medicine in the second 4 weeks: One night before going to bed, use a 5 g applicator inside the vagina and do not get up for a few hours to absorb the medicine. At the end of 8 weeks of intervention, the forms will be completed again.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Volvaginal Atrophy Mental Symptoms. Timepoint: Completion of Volvaginal Atrophy Mental Symptoms Questionnaire before intervention, end of week 4 and end of week 8 after intervention. Method of measurement: Volvaginal Atrophy Mental Symptoms Questionnaire.</prim_outcome>
      <prim_outcome>Women's sexual function index. Timepoint: Completion of women's sexual function index questionnaire before the intervention, end of week 4 and end of week 8 after the intervention. Method of measurement: Women's sexual function index questionnaire.</prim_outcome>
      <prim_outcome>Quality of life for postmenopausal women. Timepoint: Completion of quality of life evaluation questionnaire for postmenopausal women before the intervention, end of week 4 and end of week 8 after the intervention. Method of measurement: Quality of life evaluation questionnaire for postmenopausal women.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-12-24</approval_date>
        <contact_name>Ethics Committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences and Health Services, Hezar Jerib St. Esfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
